Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • US court battles block...

    US court battles block Novartis bid to sell new biosimilar

    Written by savita thakur thakur Published On 2016-09-02T10:54:12+05:30  |  Updated On 2 Sept 2016 10:54 AM IST

    Novartis has won U.S. approval for a copy of Amgen's blockbuster arthritis drug Enbrel, but the Swiss drugmaker's bid to muscle in on the medicine's $4.7 billion in annual U.S. revenue remains blocked by court battles.


    Novartis's Sandoz unit said the U.S. Food and Drug Administration (FDA) approved Erelzi, its biosimilar copy of Enbrel, for rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and other diseases.


    Yet Erelzi remains stuck in the starting blocks because U.S. courts have ruled makers of biosimilars must wait 180 days after winning FDA approval before beginning sales of the near-copies.


    That could delay Erelzi's sales launch until March 2017.


    Amgen is also waging an aggressive patent war, seeking to fend off Novartis's incursion on Enbrel's turf by arguing in U.S. federal court its drug has patent protection until 2029.


    "We are fully committed to bringing Erelzi to U.S. patients and payers as soon as possible," Novartis said in a statement, adding: "However, we cannot speculate on product commercial availability."


    Biosimilars aim to copy biologic products made inside living cells.


    Novartis, whose first biosimilar Zarxio was approved last year after a separate court fight with Amgen, is investing hundreds of millions of dollars in biosimilar manufacturing in Austria and France to make cheaper biotech copies of brand-name drugs.


    The Basel-based company is betting these copies will be irresistible for insurers, healthcare systems and governments aiming to contain costs.


    In Erelzi's case, the prize is big as Enbrel was the world's fifth-biggest selling medicine in 2014.


    In trying to accelerate sales, Novartis has petitioned the U.S. Supreme Court to overturn the ruling by a U.S. federal appeals court forcing biosimilar makers to wait six months after FDA approval.


    Meanwhile, Amgen's battle to prolong patents it maintains shield Enbrel for another 13 years is far from resolved. In an Aug. 11 ruling, a U.S. federal judge in New Jersey blocked Sandoz from selling its version.


    While court documents indicate Novartis and Amgen have struck a pact over the matter, their agreement has been sealed by U.S. District Judge Claire Cecchi and is not public.


    "We will not comment on the pending litigation at this time," Novartis said in a statement.


    However, the patent fight could take months or years to resolve. Cecchi has released a schedule for hearings, with a potential trial due to begin only in April 2018.

    AmgenapprovalEnbrelHealthcareNovartisUS District Judge Claire CecchiUS Food & Drug AdministrationUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok